Retrotope Announces RT001 Clinical Data Presentation at the 2018 American Academy of Neurology (AAN) Annual Meeting
April 24, 2018 08:00 ET | Retrotope
Positive Findings from Compassionate Use Study in Patient with Infantile Neuroaxonal Dystrophy (INAD) Presented LOS ALTOS, Calif., April 24, 2018 (GLOBE NEWSWIRE) -- Retrotope announced today...
Retrotope Announces Peer-Reviewed Publication of Positive Phase 1b/2a Findings for RT001 in Friedreich’s Ataxia
April 18, 2018 08:00 ET | Retrotope
Protocol for Pivotal Clinical Trial Has Been Submitted to the US FDA LOS ALTOS, Calif., April 18, 2018 (GLOBE NEWSWIRE) -- Retrotope announced today peer-reviewed publication of positive Phase...
US FDA Grants Orphan Drug Designation for Retrotope’s RT001 in the Treatment of Phospholipase 2G6 (PLA2G6)-Associated Neurodegeneration
November 02, 2017 09:00 ET | Retrotope
LOS ALTOS, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Retrotope announced today that the U.S. Food and Drug Administration’s (FDA’s) Office of Orphan Products Development (OOPD) granted orphan drug...
Study of Retrotope’s deuterated polyunsaturated fatty acid drugs published in The FEBS Journal
October 30, 2017 09:00 ET | Retrotope
LOS ALTOS, Calif. and TORONTO, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Retrotope and collaborators, led by Dr. Brian Bennett of Queen’s University, have published a paper entitled “Deuterium-reinforced...